Feasibility and Benefit of a Telerehabilitation Program in Human Immunodeficiency Virus-infected Patients
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Human Immunodeficiency Virus
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Enrollment
- 25
- Primary Endpoint
- Retention rate
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
The aim of this study is to assess the feasibility and the effects of a 6-week telerehabilitation on the three domains of the International Classification of Functioning, Disability and Health in HIV-infected patients under highly active antiretroviral therapy (HAART).
HIV-infected patients were randomized either into an Endurance and Resistance Training Exercise (ERTE) group or a control (CON) group. Telerehabilitation was realized in a public fitness center, with online guidance and weekly telephone advice, 3 times per week for 6 weeks. Feasibility was determined by recruitment rate, retention rate and adverse events. Secondary outcomes were impact on body composition, inflammation and coagulation (C-reactive protein, D-dimer), physical fitness and quality of life (WHOQOL-HIV).
Investigators
Caty
Principal Investigator
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Eligibility Criteria
Inclusion Criteria
- •18 years or older
- •under HAART treatment
- •native French speaker
Exclusion Criteria
- •AIDS diagnosis
- •physical and/or psychiatric impairments that seriously impaired physical activity
- •Unstable (defined by any modification of health outcomes during the last 6 months).
Outcomes
Primary Outcomes
Retention rate
Time Frame: At study completion (after 6 weeks)
Percentage of patients lost to follow-up
Adverse events
Time Frame: At study completion (after 6 weeks)
Percentage of patients who experienced one or more adverse events
Recruitment rate
Time Frame: At study completion (after 6 weeks)
Number of eligible participants who enrolled in the program out of the number were recruited
Secondary Outcomes
- Weight(Assessments at baseline and at 6 weeks)
- D-dimer(Assessments at baseline and at 12 weeks)
- Lean body mass(Assessments at baseline and at 6 weeks)
- Fat body mass(Assessments at baseline and at 6 weeks)
- C-reactive protein(Assessments at baseline and at 12 weeks)
- CD4+ T cell counts(Assessments at baseline and at 12 weeks)
- Viral load(Assessments at baseline and at 12 weeks)
- Lower body muscular strength(Assessments at baseline and at 6 weeks)
- Functional exercise capacity(Assessments at baseline and at 6 weeks)
- Flexibility(Assessments at baseline and at 6 weeks)
- Upper limb strength(Assessments at baseline and at 6 weeks)
- Quality of life(Assessments at baseline and at 6 weeks)